Name: Vascular endothelial growth factor C (VEGF-C) (VRP) - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a target name.

REQUEST A FREE TRIAL

BioCentury | Mar 26, 2025

Product Development

Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report

Plus:

BioCentury | Jan 18, 2025

Product Development

2025 catalysts: New mechanisms in obesity, neurology, ophthalmology

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

BioCentury | Jul 18, 2024

Data Byte

New AMD data showcase the promise and high bar for vectorized biologics

Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling

BioCentury | Feb 6, 2024

Product Development

Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more

Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM

BioCentury | Aug 19, 2022

Finance

Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal

First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M

BioCentury | Apr 30, 2021

Translation in Brief